On February 5, 2017 Abbisko Therapeutics, a biopharmaceutical company dedicated to discover and develop innovative medicines, reported the completion of a $28 million Series A financing from a leading group of healthcare investors, including Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and TF Capital (Press release, Abbisko Therapeutics, FEB 5, 2017, View Source;article_id=43 [SID1234521011]).

The proceeds will be used to support Abbisko Therapeutics’ drug research and development effort, including the creation of a state-of-the-art R&D center and advancing a drug discovery pipeline with multiple programs in oncology and other disease areas.

"We are fortunate to have a number of the world’s premier healthcare investors participated in this round of financing." said Dr. Yao-chang Xu, founder and CEO of Abbisko. "We have a new but highly experienced drug research and development team. Investors agree with our strategy and philosophy, providing strong financing support to enable our quick start. We will seize the opportunities to become a critical force and leading company in the discovery of novel medicines in China and the world. We hope to bring revolutionary therapeutic solutions to patient as soon as possible".

"At present, China’s innovative drug discovery is in a golden period of time with vigorous development and progress. In a very rapid fashion, Abbisko has built up a top notch R&D team and established a strong pipeline." said Ai’min Wu, Partner and President of Sinopharm Capital. "Sinopharm Capital fully recognizes Abbisko’s expertise and strategy and believes in that, under the leadership of Dr. Yao-chang Xu and the management team, Abbisko has a great potential to become one of the leading biopharmaceutical companies in China and in the industry. Sinopharm Capital is pleased to participate the creation and development of Abbisko Therapeutics and will continue to dedicate in helping domestic biomedical companies to be competitive with international leading players.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!